Changes

Jump to navigation Jump to search
**ACELEROX is developing novel antioxidant nanoparticles that serve as therapies for reactive oxygen species (ROS)-mediated disease. ROS has been implicated in the progression of a broad range of diseases, including rheumatoid arthritis, multiple sclerosis, ischemic stroke and traumatic brain injury. The company’s proprietary class of molecules, termed PEG-HCCs, can be used to directly treat the symptoms of these diseases as well as to deliver chemotherapeutic drugs into tumors.
*ACF Pharmaceuticals
**ACF PHARMACEUTICALS is a pre-clinical stage company testing novel molecules targeting the PGE2 pathway, which is important in cancer, fibrosis, inflammation and pain, in a unique partnership with a private chemical company and a research institution.
*Apaxis Medical
**
*Apaxis Medical
*Brevitest Technologies
**
*Clearview App
**
*Guidabot
**
*NewHeart
**
*Procyrion
**VC funding
*Pulmotect
**
==Leadership Team==

Navigation menu